文献速递乳腺技术与安全MR

乳腺DWI在钆对比剂注射前后分析——1.5 T与3.0 T下的患者自身对照研究

Breast DWI Analyzed Before and After Gadolinium Contrast Administration-An Intrapatient Analysis on 1.5 T and 3.0 T.
PubMed 文献 · Invest Radiol · 2023-06-30

本研究纳入筛查或术前乳腺MRI(1.5 T/3 T),于钆特酸葡胺注射前及注射后约2分钟采集扩散加权成像,比较纤维腺体组织及良恶性病变基于二维ROI的表观扩散系数。结果显示对比剂注射后ADC均值无显著变化,18%病灶扩散水平发生偏移,总体加权κ为0.75,支持在缩短的多参数MRI方案中将DWI置于对比剂注射后2分钟采集。

要点

  • 对比剂注射后约2分钟采集DWI,纤维腺体组织及良恶性病灶ADC均值无显著变化。
  • 18%病灶扩散水平发生偏移,总体加权κ为0.75。
  • ADC基于b150-b800计算时,可将DWI置于对比剂注射后2分钟而不增加扫描时间。

核心结论

  • 本研究支持在缩短的多参数乳腺MRI方案中,于15 mL 0.5 M钆特酸葡胺注射后2分钟采集DWI并以b150-b800计算ADC,无需额外扫描时间。

研究设计与样本

  • 患者自身对照研究,纳入筛查或术前乳腺MRI(1.5 T/3 T),DWI采用单次激发自旋回波-回波平面成像,于钆特酸葡胺注射前及注射后约2分钟采集;21例患者37个健康纤维腺体组织ROI及93例患者93个良恶性病灶ROI,采用Wilcoxon符号秩检验比较ADC,加权κ比较扩散水平。

诊断标准与关键数值

  • 对比剂注射后ADC均值在21例患者37个健康纤维腺体组织ROI中无显著变化。
  • 对比剂注射后ADC均值在93例患者93个良恶性病灶中无显著变化,按B0分层后该效应仍存在。
  • 18%的病灶观察到扩散水平偏移,总体加权κ为0.75。
  • 以b150-b800计算ADC,DWI于15 mL 0.5 M钆特酸葡胺注射后2分钟采集。

临床应用与阅片要点

  • 作者结论支持在缩短的多参数乳腺MRI方案中将DWI置于对比剂注射后2分钟采集,以b150-b800计算ADC,不增加扫描时间。
  • 判读时需注意约18%病灶在对比剂注射后扩散水平发生偏移,总体加权κ为0.75。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: Diffusion-weighted magnetic resonance imaging (MRI) is gaining popularity as an addition to standard dynamic contrast-enhanced breast MRI. Although adding diffusion-weighted imaging (DWI) to the standard protocol design would require increased scanning-time, implementation during the contrast-enhanced phase could offer a multiparametric MRI protocol without any additional scanning time. However, gadolinium within a region of interest (ROI) might affect assessments of DWI. This study aims to determine if acquiring DWI postcontrast, incorporated in an abbreviated MRI protocol, would statistically significantly affect lesion classification. In addition, the effect of postcontrast DWI on breast parenchyma was studied.

MATERIALS AND METHODS: Screening or preoperative MRIs (1.5 T/3 T) were included for this study. Diffusion-weighted imaging was acquired with single-shot spin echo-echo planar imaging before and at approximately 2 minutes after gadoterate meglumine injection. Apparent diffusion coefficients (ADCs) based on 2-dimensional ROIs of fibroglandular tissue, as well as benign and malignant lesions at 1.5 T/3.0 T, were compared with a Wilcoxon signed rank test. Diffusivity levels were compared between precontrast and postcontrast DWI with weighted κ. An overall P ≤ 0.05 was considered statistically significant.

RESULTS: No significant changes were observed in ADC mean after contrast administration in 21 patients with 37 ROI of healthy fibroglandular tissue and in the 93 patients with 93 (malignant and benign) lesions. This effect remained after stratification on B 0 . In 18% of all lesions, a diffusion level shift was observed, with an overall weighted κ of 0.75.

CONCLUSIONS: This study supports incorporating DWI at 2 minutes postcontrast when ADC is calculated based on b150-b800 with 15 mL 0.5 M gadoterate meglumine in an abbreviated multiparametric MRI protocol without requiring extra scan time.

来源:Invest Radiol,查看原文。版权归原作者所有。

引用

  1. van der Hoogt, Schipper, Wessels, et al. Breast DWI Analyzed Before and After Gadolinium Contrast Administration-An Intrapatient Analysis on 1.5 T and 3.0 T. Invest Radiol. 2023. PMID: 37389456. doi:10.1097/RLI.0000000000000999

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。